Azenta Life Sciences Reports Preliminary Results of Second Quarter of Fiscal 2022, Ended March 31, 2022
Robust customer demand bolstered by operational execution drives strong second quarter results
CHELMSFORD, Mass., May 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported preliminary financial results for the second quarter ended March 31, 2022.
Summary of Preliminary Results
On February 1, 2022, the Company completed the sale of its Semiconductor Automation business. The related gain on the sale and the results of the Semiconductor Automation business are treated as discontinued operations and reflected in total diluted EPS. Due to the complexities of the financial carve-out of the business from the Company's financial results, the Company expects it will require additional time to finalize its financial statements and intends to file a Form 12b-25 with the Securities and Exchange Commission in order to extend the due date of its quarterly report on Form 10-Q for the quarter ended March 31, 2022 for five days, as permitted by Rule 12b-25 under the Securities Exchange Act. As a result, the financial results presented herein are preliminary.
Quarter Ended | ||||||||||||||||
Dollars in millions, except per share data | March 31, | December 31, | March 31, | Change | ||||||||||||
2022 | 2021 | 2021 | Prior Qtr. | Prior Yr. | ||||||||||||
Revenue from Continuing Operations | $ | 146 | $ | 140 | $ | 130 | 4 | % | 12 | % | ||||||
Life Sciences Products | $ | 54 | $ | 50 | $ | 52 | 7 | % | 2 | % | ||||||
Life Sciences Services | $ | 92 | $ | 90 | $ | 77 | 2 | % | 19 | % | ||||||
Diluted EPS Continuing Operations | $ | (0.02) | $ | 0.04 | $ | (0.10) | (163) | % | 75 | % | ||||||
Diluted EPS Total | $ | 28.15 | $ | 0.58 | $ | 0.32 | NM | NM | % | |||||||
Non-GAAP Diluted EPS Continuing Operations | $ | 0.12 | $ | 0.12 | $ | 0.14 | (2) | % | (15) | % | ||||||
Adjusted EBITDA Continuing Operations | $ | 19 | $ | 20 | $ | 24 | (2) | % | (18) | % | ||||||
Management Comments
"We delivered another strong quarter with healthy demand across the portfolio," stated Steve Schwartz, President and CEO. "Even as we faced COVID headwinds in certain regions, the team did a remarkable job to mitigate the impact to the business. We continued to enhance our commercial positioning as Azenta and see a long runway ahead driven by our unique value proposition in strong and fast-growing end markets."
Summary of Preliminary Q2 GAAP Results
- Revenue from continuing operations for the second quarter was $146 million, up 12% year over year and up 4% sequentially. Year-over-year organic growth was 12%.
- Revenue from Life Sciences Products grew 2% year over year driven by continued strength in automated cryogenic freezers partially offset by lower consumables and instruments revenue, which saw the peak of estimated COVID-related revenue in the second quarter of fiscal year 2021. On a sequential basis, revenue was up 7% driven by growth in automated stores and non-COVID related consumables and instruments revenue.
- Life Sciences Services revenue was up 19% year over year, with 21% growth in Sample Repository Solutions driven by growth in storage and 18% growth in Genomics Services. On a sequential basis, revenue was up 2% with expansion in both businesses.
- Operating loss for the second quarter was $5 million. Gross margin was 48.7% and operating expense of $76 million included approximately $6 million of professional fees in support of M&A initiatives primarily related to the sale.
- Diluted EPS from continuing operations was ($0.02) per share. Total diluted EPS of $28.15 includes $28.18 of diluted EPS from discontinued operations.
Summary of Preliminary Q2 Non-GAAP Earnings for Continuing Operations
The Continuing Operations view shown on a non-GAAP basis provides additional performance information by excluding the impact of M&A costs, amortization, restructuring, purchase price accounting, certain tax impacts, and special charges or gains, such as impairment losses.
- As referenced above, revenue in the second quarter was $146 million, up 12% year over year, with 2% growth in Life Sciences Products and 19% growth in Life Science Services.
- Gross margin of 49.6% was lower by 90 basis points year over year and up 30 basis points sequentially. The gross margin of the Products business was 49.5%, up 310 basis points year over year and up 360 basis points sequentially. The gross margin of the Services business was 49.6%, lower by 360 basis points year over year and down 150 basis points sequentially. Operating income was $10 million and operating margin was 6.7%, down 350 basis points year over year and down 210 basis points sequentially. Operating expense in the quarter was $62 million, up $6 million compared to Q1 2022 and up $10 million year over year. The increases include investments in R&D, sales, and G&A to support growth. Adjusted EBITDA, which excludes stock-based compensation, was $19 million and Adjusted EBITDA margin was 13.3%, down 90 basis points from the first quarter of 2022 and down 500 basis points year over year.
- Diluted EPS for the second quarter was $0.12, flat compared to the first quarter and down $0.02 versus one year ago.
Cash and Liquidity
- The Company completed the sale of its Semiconductor Automation business on February 1, 2022 to Thomas H. Lee Partners for a cash price of $3.0 billion, subject to final working capital and other adjustments. Net cash proceeds from the divestiture are expected to be approximately $2.5 billion excluding estimated taxes payable and other items, such as closing costs. Upon closure of the sale on February 1, 2022, the Company utilized approximately $50 million of proceeds to extinguish all outstanding debt. The Company also terminated its revolving line of credit, which had no borrowings outstanding.
- The Company ended the second fiscal quarter of 2022 with a total balance of cash, cash equivalents, restricted cash and marketable securities of $3.0 billion. The company has pending taxes due of approximately $450 million related to the gain on the sale, the majority of which is expected to be paid in the fiscal third quarter.
Guidance for Continuing Operations for Third Quarter Fiscal 2022
The Company announced revenue and earnings guidance for continuing operations for the third quarter of fiscal 2022. Revenue is expected to be in the range of $140 million to $150 million and non-GAAP diluted earnings per share for the third fiscal quarter is expected to be in the range of $0.09 to $0.17. GAAP diluted earnings per share from continuing operations is expected to be in the range of ($0.03) to $0.05.
Conference Call and Webcast
Azenta management will webcast its second quarter earnings conference call today at 4:30 p.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.
The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events, and will be archived online on this website for convenient on-demand replay. In addition, you may call 800-926-6194 (US & Canada only) or +1-212-231-2922 for international callers to listen to the live webcast.
Regulation G – Use of Non-GAAP financial Measures
The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets, statements of operations and statements of cash flows.
"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Also, as noted above, the results included in this release are preliminary. In the course of finalizing its quarterly closing and reporting processes and the completing its financial statements for the quarter ended March 31, 2022, the Company may identify items that would require the Company to make adjustments, some of which could be material, to the preliminary financial results set forth in this release. Other forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to increase our profitability, our ability to improve or retain our market position, our ability to deliver financial success in the future, and our ability to invest the cash proceeds from the sale of our semiconductor automation business. Factors that could cause results to differ from our expectations include the following: the impact of the COVID-19 global pandemic on the markets we serve, including our supply chain, and on the global economy generally, the volatility of the life sciences industries the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; the timing and effectiveness of cost reduction and cost control measures; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.
About Azenta Life Sciences
Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December 1st, the company changed its name and ticker to Azenta, Inc. (NASDAQ:AZTA) from Brooks Automation, Inc, (NASDAQ:BRKS).
Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
AZENTA INVESTOR CONTACTS:
Sara Silverman
Director of Investor Relations
Azenta Life Sciences
978.262.2635
[email protected]
Sherry Dinsmore
Azenta Life Sciences
978.262.4301
[email protected]
AZENTA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) | |||||||||||||||
(In thousands, except per share data) | |||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||
March 31, | March 31, | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Revenue | |||||||||||||||
Products | $ | 49,449 | $ | 46,233 | $ | 95,318 | $ | 87,695 | |||||||
Services | 96,095 | 83,302 | 189,878 | 159,982 | |||||||||||
Total revenue | 145,544 | 129,535 | 285,196 | 247,677 | |||||||||||
Cost of revenue | |||||||||||||||
Products | 24,952 | 22,787 | 49,475 | 45,580 | |||||||||||
Services | 49,766 | 48,848 | 97,852 | 86,862 | |||||||||||
Total cost of revenue | 74,719 | 71,635 | 147,327 | 132,442 | |||||||||||
Gross profit | 70,825 | 57,900 | 137,869 | 115,235 | |||||||||||
Operating expenses | |||||||||||||||
Research and development | 6,896 | 5,236 | 13,381 | 10,324 | |||||||||||
Selling, general and administrative | 68,515 | 61,892 | 129,226 | 113,823 | |||||||||||
Restructuring charges | 122 | 92 | 296 | 53 | |||||||||||
Total operating expenses | 75,533 | 67,220 | 142,902 | 124,200 | |||||||||||
Operating loss | (4,708) | (9,320) | (5,033) | (8,965) | |||||||||||
Interest income | 3,076 | 18 | 3,111 | 94 | |||||||||||
Interest expense | (1,555) | (452) | (2,010) | (1,008) | |||||||||||
Loss on extinguishment of debt | (632) | — | (632) | — | |||||||||||
Other income (expenses), net | (1,170) | 108 | (2,248) | 1,389 | |||||||||||
Loss before income taxes | (4,989) | (9,646) | (6,812) | (8,490) | |||||||||||
Income tax benefit | (3,173) | (2,310) | (7,853) | (3,860) | |||||||||||
(Loss) income from continuing operations | (1,816) | (7,336) | 1,041 | (4,630) | |||||||||||
Income from discontinued operations, net of tax | 2,117,685 | 31,084 | 2,158,147 | 54,406 | |||||||||||
Net income | $ | 2,115,869 | $ | 23,748 | $ | 2,159,188 | $ | 49,776 | |||||||
Basic net income per share: | |||||||||||||||
(Loss) income from continuing operations | $ | (0.02) | $ | (0.10) | $ | 0.01 | $ | (0.06) | |||||||
Income from discontinued operations, net of tax | 28.25 | 0.42 | 28.84 | 0.73 | |||||||||||
Basic net income per share | $ | 28.23 | $ | 0.32 | $ | 28.86 | $ | 0.67 | |||||||
Diluted net income per share: | |||||||||||||||
(Loss) income from continuing operations | $ | (0.02) | $ | (0.10) | $ | 0.01 | $ | (0.06) | |||||||
Income from discontinued operations, net of tax | 28.18 | 0.42 | 28.72 | 0.73 | |||||||||||
Diluted net income per share | $ | 28.15 | $ | 0.32 | $ | 28.73 | $ | 0.67 | |||||||
Weighted average shares outstanding used in computing net income per share: | |||||||||||||||
Basic | 74,958 | 74,265 | 74,823 | 74,142 | |||||||||||
Diluted | 75,157 | 74,414 | 75,145 | 74,367 | |||||||||||
AZENTA, INC. CONSOLIDATED BALANCE SHEETS (unaudited) (In thousands, except share and per share data) | |||||
March 31, | September 30, | ||||
2022 | 2021 | ||||
Assets | |||||
Current assets | |||||
Cash and cash equivalents | $ | 1,936,291 | $ | 227,427 | |
Marketable securities | 816,512 | 81 | |||
Accounts receivable, net | 137,578 | 119,877 | |||
Inventories | 77,752 | 60,398 | |||
Prepaid expenses and other current assets | 74,961 | 58,198 | |||
Current assets held for sale | — | 311,385 | |||
Total current assets | 3,043,094 | 777,366 | |||
Property, plant and equipment, net | 150,426 | 130,719 | |||
Long-term marketable securities | 260,219 | 3,598 | |||
Long-term deferred tax assets | 2,278 | 10,043 | |||
Goodwill | 467,746 | 469,356 | |||
Intangible assets, net | 170,507 | 186,534 | |||
Other assets | 65,239 | 58,068 | |||
Non-current assets held for sale | — | 183,828 | |||
Total assets | $ | 4,159,509 | $ | 1,819,512 | |
Liabilities and Stockholders' Equity | |||||
Current liabilities | |||||
Accounts payable | $ | 35,868 | $ | 42,360 | |
Deferred revenue | 30,701 | 25,724 | |||
Accrued warranty and retrofit costs | 2,492 | 2,330 | |||
Accrued compensation and benefits | 41,707 | 33,183 | |||
Accrued restructuring costs | 183 | 304 | |||
Accrued income taxes payable | 430,650 | 8,711 | |||
Deferred tax liabilities | 2,676 | — | |||
Accrued expenses and other current liabilities | 71,691 | 103,537 | |||
Current liabilities held for sale | — | 128,939 | |||
Total current liabilities | 615,968 | 345,088 | |||
Long-term debt | — | 49,677 | |||
Long-term tax reserves | 2,023 | 1,973 | |||
Long-term deferred tax liabilities | 18,429 | 13,030 | |||
Long-term pension liabilities | 720 | 705 | |||
Long-term operating lease liabilities | 48,698 | 45,088 | |||
Other long-term liabilities | 4,790 | 6,173 | |||
Non-current liabilities held for sale | — | 32,444 | |||
Total liabilities | 690,628 | 494,178 | |||
Commitments and contingencies | |||||
Stockholders' Equity | |||||
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding | — | — | |||
Common stock, $0.01 par value - 125,000,000 shares authorized, 88,445,490 shares issued and 74,983,621 shares outstanding at March 31, 2022, 87,808,922 shares issued and 74,347,053 shares outstanding at September 30, 2021 | 885 | 878 | |||
Additional paid-in capital | 1,970,128 | 1,976,112 | |||
Accumulated other comprehensive income | 17,645 | 19,351 | |||
Treasury stock at cost - 13,461,869 shares | (200,956) | (200,956) | |||
Accumulated earnings (deficit) | 1,681,179 | (470,051) | |||
Total stockholders' equity | 3,468,881 | 1,325,334 | |||
Total liabilities and stockholders' equity | $ | 4,159,509 | $ | 1,819,512 | |
Notes on Non-GAAP Financial Measures
Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.
Quarter Ended | ||||||||||||||||||
March 31, 2022 | December 31, 2021 | March 31, 2021 | ||||||||||||||||
per diluted | per diluted | per diluted | ||||||||||||||||
Dollars in thousands, except per share data | $ | share | $ | share | $ | share | ||||||||||||
Net (loss) income from continuing operations | $ | (1,816) | $ | (0.02) | $ | 2,858 | $ | 0.04 | $ | (7,336) | $ | (0.10) | ||||||
Adjustments: | ||||||||||||||||||
Amortization of intangible assets | 7,887 | 0.10 | 8,046 | 0.11 | 9,377 | 0.13 | ||||||||||||
Restructuring charges | 122 | 0.00 | 173 | 0.00 | 92 | 0.00 | ||||||||||||
Tariff adjustment | (486) | — | — | 5,497 | 0.07 | |||||||||||||
Merger and acquisition costs | 5,589 | 0.07 | 3,719 | 0.05 | 7,517 | 0.10 | ||||||||||||
Rebranding and transformation costs | 1,297 | 0.02 | 619 | 0.01 | — | — | ||||||||||||
Loss on extinguishment of debt | 632 | 0.01 | — | — | — | — | ||||||||||||
Tax adjustments (1) | (900) | (0.01) | (4,240) | (0.06) | (2,264) | (0.03) | ||||||||||||
Tax effect of adjustments | (3,580) | (0.05) | (2,265) | (0.03) | (2,672) | (0.04) | ||||||||||||
Non-GAAP adjusted net income from continuing operations | $ | 8,745 | $ | 0.12 | $ | 8,910 | $ | 0.12 | $ | 10,211 | $ | 0.14 | ||||||
Stock based compensation, pre-tax | 5,549 | 0.07 | 3,458 | 0.05 | 5,734 | 0.08 | ||||||||||||
Tax rate | 15 | % | — | 15 | % | — | 15 | % | — | |||||||||
Stock-based compensation, net of tax | 4,717 | 0.06 | 2,939 | 0.04 | 4,874 | 0.07 | ||||||||||||
Non-GAAP adjusted net income excluding stock-based compensation - continuing operations | $ | 13,461 | $ | 0.18 | $ | 11,850 | $ | 0.16 | $ | 15,085 | $ | 0.20 | ||||||
Shares used in computing non-GAAP diluted net income per share | — | 75,157 | — | 74,866 | — | 74,367 | ||||||||||||
Six Months Ended | |||||||||||||
March 31, 2022 | March 31, 2021 | ||||||||||||
per diluted | per diluted | ||||||||||||
Dollars in thousands, except per share data | $ | share | $ | share | |||||||||
Net income (loss) from continuing operations | $ | 1,041 | $ | 0.01 | $ | (4,630) | $ | (0.06) | |||||
Adjustments: | |||||||||||||
Amortization of intangible assets | 15,933 | 0.21 | 18,287 | 0.25 | |||||||||
Tariff adjustment | (486) | (0.01) | 5,497 | 0.07 | |||||||||
Merger and acquisition costs | 9,308 | 0.12 | 9,708 | 0.13 | |||||||||
Restructuring related charges | 296 | 0.00 | 53 | 0.00 | |||||||||
Rebranding and transformation costs | 1,916 | 0.03 | — | — | |||||||||
Loss on extinguishment of debt | 632 | 0.01 | — | — | |||||||||
Tax adjustments (1) | (4,760) | (0.06) | (863) | (0.01) | |||||||||
Tax effect of adjustments | (6,225) | (0.08) | (8,548) | (0.11) | |||||||||
Non-GAAP adjusted net income from continuing operations | $ | 17,655 | $ | 0.23 | $ | 19,504 | $ | 0.26 | |||||
Stock-based compensation, pre-tax | 9,007 | 0.12 | 10,569 | 0.14 | |||||||||
Tax rate | 15 | % | — | 15 | % | — | |||||||
Stock-based compensation, net of tax | 7,656 | $ | 0.10 | 8,984 | 0.12 | ||||||||
Non-GAAP adjusted net income excluding stock-based compensation - continuing operations | $ | 25,311 | $ | 0.34 | $ | 28,488 | $ | 0.38 | |||||
Shares used in computing non-GAAP diluted net income per share | — | 75,145 | — | 74,367 | |||||||||
(1) Tax adjustments during all periods include adjustments to tax benefits related to stock compensation windfalls. These benefits are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting. Tax adjustments for the quarter and six months ended March 31, 2022, include a $2.5M increase to expense related to the exclusion of allocations between continuing operations and discontinued operations. This amount is partially offset by the windfall adjustment and the exclusion of a $0.6M charge for the impact of a state tax rate change related to the separation.
Quarter Ended | Six Months Ended | ||||||||||||||
March 31, | December 31, | March 31, | March 31, | March 31, | |||||||||||
Dollars in thousands | 2022 | 2021 | 2021 | 2022 | 2021 | ||||||||||
GAAP net income | $ | 2,115,869 | $ | 43,320 | $ | 23,748 | $ | 2,159,188 | $ | 49,776 | |||||
Adjustments: | |||||||||||||||
Less: Income from discontinued operations | (2,117,685) | (40,462) | (31,084) | (2,158,147) | (54,406) | ||||||||||
Less: Interest income | (3,076) | (35) | (18) | (3,111) | (94) | ||||||||||
Add: Interest expense | 1,555 | 455 | 452 | 2,010 | 1,008 | ||||||||||
Add: Income tax benefit | (3,173) | (4,680) | (2,310) | (7,853) | (3,860) | ||||||||||
Add: Depreciation | 5,316 | 5,208 | 4,743 | 10,524 | 9,560 | ||||||||||
Add: Amortization of completed technology | 1,840 | 1,773 | 2,021 | 3,613 | 4,026 | ||||||||||
Add: Amortization of customer relationships and acquired intangible assets | 6,047 | 6,272 | 7,356 | 12,319 | 14,261 | ||||||||||
Loss on extinguishment of debt | 632 | 632 | |||||||||||||
Earnings before interest, taxes, depreciation and amortization | $ | 7,325 | $ | 11,851 | $ | 4,908 | $ | 19,175 | $ | 20,271 | |||||
Quarter Ended | Six Months Ended | ||||||||||||||
March 31, | December 31, | March 31, | March 31, | March 31, | |||||||||||
Dollars in thousands | 2022 | 2021 | 2021 | 2022 | 2021 | ||||||||||
Earnings before interest, taxes, depreciation and amortization | $ | 7,325 | $ | 11,851 | $ | 4,908 | $ | 19,175 | $ | 20,271 | |||||
Adjustments: | |||||||||||||||
Add: Stock-based compensation | 5,549 | 3,458 | 5,734 | 9,007 | 10,569 | ||||||||||
Add: Restructuring charges | 122 | 173 | 92 | 296 | 53 | ||||||||||
Add: Merger and acquisition costs | 5,589 | 3,719 | 7,517 | 9,308 | 9,708 | ||||||||||
Add: Tariff adjustment | (486) | — | 5,497 | (486) | 5,497 | ||||||||||
Rebranding and transformation costs | 1,297 | 619 | — | 1,916 | — | ||||||||||
Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations | $ | 19,396 | $ | 19,820 | $ | 23,748 | $ | 39,216 | $ | 46,098 | |||||
Quarter Ended | ||||||||||||||||||
Dollars in thousands | March 31, 2022 | December 31, 2021 | March 31, 2021 | |||||||||||||||
GAAP gross profit | $ | 70,825 | 48.7 | % | $ | 67,044 | 48.0 | % | $ | 57,900 | 44.7 | % | ||||||
Adjustments: | ||||||||||||||||||
Amortization of completed technology | 1,840 | 1.3 | 1,773 | 1.3 | 2,021 | 1.6 | ||||||||||||
Tariff adjustment | (486) | (0.3) | — | — | 5,497 | 4.2 | ||||||||||||
Non-GAAP adjusted gross profit | $ | 72,179 | 49.6 | % | $ | 68,817 | 49.3 | % | $ | 65,418 | 50.5 | % | ||||||
Life Sciences Products | Life Sciences Services | |||||||||||||||||||||||||||||||||||
Quarter Ended | Quarter Ended | |||||||||||||||||||||||||||||||||||
Dollars in thousands | March 31, 2022 | December 31, 2021 | March 31, 2021 | March 31, 2022 | December 31, 2021 | March 31, 2021 | ||||||||||||||||||||||||||||||
GAAP gross profit | $ | 26,290 | 49.0 | % | $ | 22,690 | 45.5 | % | $ | 24,051 | 45.9 | % | $ | 44,535 | 48.4 | % | $ | 44,354 | 49.4 | % | $ | 33,849 | 43.9 | % | ||||||||||||
Adjustments: | ||||||||||||||||||||||||||||||||||||
Amortization of completed technology | 267 | 0.5 | 203 | 0.4 | 280 | 0.5 | 1,572 | 1.7 | 1,570 | 1.7 | 1,741 | 2.3 | ||||||||||||||||||||||||
Tariff adjustment | — | — | — | — | — | — | (486) | (0.5) | — | — | 5,497 | 7.1 | ||||||||||||||||||||||||
Non-GAAP adjusted gross profit | $ | 26,557 | 49.5 | % | $ | 22,894 | 45.9 | % | $ | 24,331 | 46.5 | % | $ | 45,621 | 49.6 | % | $ | 45,924 | 51.2 | % | $ | 41,087 | 53.2 | % | ||||||||||||
Six Months Ended | ||||||||||||
Dollars in thousands | March 31, 2022 | March 31, 2021 | ||||||||||
GAAP gross profit | $ | 137,869 | 48.3 | % | $ | 115,235 | 46.5 | % | ||||
Adjustments: | ||||||||||||
Amortization of completed technology | 3,613 | 1.3 | 4,026 | 1.6 | ||||||||
Tariff adjustment | (486) | (0.2) | 5,497 | 2.2 | ||||||||
Non-GAAP adjusted gross profit | $ | 140,996 | 49.4 | % | $ | 124,758 | 50.4 | % | ||||
Life Sciences Products | Life Sciences Services | ||||||||||||||||||||||
Six Months Ended | Six Months Ended | ||||||||||||||||||||||
Dollars in thousands | March 31, 2022 | March 31, 2021 | March 31, 2022 | March 31, 2021 | |||||||||||||||||||
GAAP gross profit | $ | 48,980 | 47.3 | % | $ | 44,576 | 45.5 | % | $ | 88,902 | 48.9 | % | $ | 70,659 | 47.2 | % | |||||||
Adjustments: | |||||||||||||||||||||||
Amortization of completed technology | 471 | 0.5 | 553 | 0.6 | 3,142 | 1.7 | 3,473 | 2.3 | |||||||||||||||
Tariff adjustment | — | — | — | — | (486) | (0.3) | 5,497 | 3.7 | |||||||||||||||
Non-GAAP adjusted gross profit | $ | 49,451 | 47.8 | % | $ | 45,129 | 46.1 | % | $ | 91,558 | 50.4 | % | $ | 79,629 | 53.2 | % | |||||||
Life Sciences Products | Life Sciences Services | |||||||||||||||||
Quarter Ended | Quarter Ended | |||||||||||||||||
March 31, | December 31, | March 31, | March 31, | December 31, | March 31, | |||||||||||||
Dollars in thousands | 2022 | 2021 | 2021 | 2022 | 2021 | 2021 | ||||||||||||
GAAP operating profit (loss) | $ | 5,021 | $ | 4,187 | $ | 6,968 | $ | 3,770 | $ | 6,314 | $ | (1,624) | ||||||
Adjustments: | ||||||||||||||||||
Amortization of completed technology | 267 | 203 | 280 | 1,572 | 1,570 | 1,741 | ||||||||||||
Tariff adjustment | — | — | — | (486) | — | 5,497 | ||||||||||||
Non-GAAP adjusted operating profit | $ | 5,288 | $ | 4,390 | $ | 7,248 | $ | 4,856 | $ | 7,884 | $ | 5,614 | ||||||
Total Segments | Corporate | Total | |||||||||||||||||||||||||
Quarter Ended | Quarter Ended | Quarter Ended | |||||||||||||||||||||||||
March 31, | December 31, | March 31, | March 31, | December 31, | March 31, | March 31, | December 31, | March 31, | |||||||||||||||||||
Dollars in thousands | 2022 | 2021 | 2021 | 2022 | 2021 | 2021 | 2022 | 2021 | 2021 | ||||||||||||||||||
GAAP operating profit (loss) | $ | 8,791 | $ | 10,501 | $ | 5,344 | $ | (13,499) | $ | (10,826) | $ | (14,664) | $ | (4,708) | $ | (325) | $ | (9,320) | |||||||||
Adjustments: | |||||||||||||||||||||||||||
Amortization of completed technology | 1,840 | 1,773 | 2,021 | — | — | — | 1,840 | 1,773 | 2,021 | ||||||||||||||||||
Amortization of customer relationships and acquired intangible assets | — | — | — | 6,047 | 6,272 | 7,356 | 6,047 | 6,272 | 7,356 | ||||||||||||||||||
Restructuring charges | — | — | — | 122 | 173 | 92 | 122 | 173 | 92 | ||||||||||||||||||
Tariff adjustment | (486) | — | 5,497 | — | — | — | (486) | — | 5,497 | ||||||||||||||||||
Rebranding and transformation costs | — | — | — | 1,297 | 619 | — | 1,297 | 619 | — | ||||||||||||||||||
Merger and acquisition costs | — | — | — | 5,589 | 3,719 | 7,517 | 5,589 | 3,719 | 7,517 | ||||||||||||||||||
Non-GAAP adjusted operating profit (loss) | $ | 10,145 | $ | 12,274 | $ | 12,862 | $ | (444) | $ | (43) | $ | 301 | $ | 9,701 | $ | 12,231 | $ | 13,162 | |||||||||
Life Sciences Products | Life Sciences Services | |||||||||||
Six Months Ended | Six Months Ended | |||||||||||
Dollars in thousands | March 31, | March 31, | March 31, | March 31, | ||||||||
2022 | 2021 | 2022 | 2021 | |||||||||
GAAP operating profit | $ | 9,208 | $ | 10,878 | $ | 10,084 | $ | 3,572 | ||||
Adjustments: | ||||||||||||
Amortization of completed technology | 471 | 553 | 3,142 | 3,473 | ||||||||
Tariff adjustment | — | — | (486) | 5,497 | ||||||||
Non-GAAP adjusted operating profit | $ | 9,679 | $ | 11,431 | $ | 12,740 | $ | 12,542 | ||||
Total Segments | Corporate | Total | ||||||||||||||||
Six Months Ended | Six Months Ended | Six Months Ended | ||||||||||||||||
Dollars in thousands | March 31, | March 31, | March 31, | March 31, | March 31, | March 31, | ||||||||||||
2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||
GAAP operating profit (loss) | $ | 19,292 | $ | 14,450 | $ | (24,325) | $ | (23,415) | $ | (5,033) | $ | (8,965) | ||||||
Adjustments: | ||||||||||||||||||
Amortization of completed technology | 3,613 | 4,026 | — | — | 3,613 | 4,026 | ||||||||||||
Amortization of customer relationships and acquired intangible assets | — | — | 12,319 | 14,261 | 12,319 | 14,261 | ||||||||||||
Restructuring charges | — | — | 296 | 53 | 296 | 53 | ||||||||||||
Tariff adjustment | (486) | 5,497 | — | — | (486) | 5,497 | ||||||||||||
Rebranding and transformation costs | — | 1,916 | 1,916 | — | ||||||||||||||
Merger and acquisition costs | — | — | 9,308 | 9,708 | 9,308 | 9,708 | ||||||||||||
Non-GAAP adjusted operating profit (loss) | $ | 22,419 | $ | 23,973 | $ | (486) | $ | 607 | $ | 21,933 | $ | 24,580 | ||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-life-sciences-reports-preliminary-results-of-second-quarter-of-fiscal-2022-ended-march-31-2022-301542955.html
SOURCE Azenta, Inc.